Current portfolio

Certara

The global leader in model-informed drug development and regulatory science, focused on optimizing drug development and improving health outcomes

Certara is the best-in-class provider of regulatory science, writing, and submission management software and services

  • Sektor
    Healthcare
  • Land
    United States
  • Ansvarig Advisor
    Eric Liu
  • Fond
    EQT VII
  • Entry
    2017
  • Web
3

Certara

  • Societal Contribution

  • 3Good health and well-being
  • 10Reduced inequalities
Logo

About Certara
Certara is the leading provider of model-informed drug development technology and services, as well as a best-in-class provider of regulatory science, writing, and submission management software and services. Certara’s solutions help inform the drug development and regulatory approval process and address the key efficacy, safety, productivity and commercial challenges facing the biopharma industry. The Company serves 1,200 commercial companies, 250 academic institutions and numerous regulatory agencies, across 60 countries. Certara is headquartered in Princeton, New Jersey with over 850 employees globally, including key operations and senior management in Northern Europe.

Market trends and drivers
Certara operates in fast-growing, niche markets which address critical needs for Certara’s pharma clients. Biosimulation market growth is driven by pharma clients’ need to optimize R&D spend, as well growing regulatory acceptance of model-informed drug development techniques. Regulatory science growth is driven by increasing outsourcing of regulatory writing and the increasing complexity of the regulatory approval process.

Investment potential
EQT VII is keen to support the continued growth of Certara, both domestically and internationally, particularly through continued investment in next generation technology, further international expansion and complementary acquisitions.

Board of directors

  • Chairperson
    Sheri McCoy
  • Board member
    James Cashman
  • Board member
    Ethan Waxman
  • Board member
    Eric Liu
  • Board member
    Mason Slaine
  • Board member
    Matthew Walsh
  • Board member
    Steve McLean

Management

  • CEO
    William Feehery
  • CFO
    Andrew Schemick

Prenumerera

Prenumerera på EQT:s press releaser, regulatoriska press releaser och updates.

Typ av nyheter
Preferred language
EQT logo
En syftesdriven global investeringsorganisation
© EQT AB 2021. EQT AB (PUBL). REGISTRATED OFFICE IN STOCKHOLM, SWEDEN. REGISTRATION NUMBER: 556849-4180